The Patient Partnership Index (PPI), the leading benchmark celebrating best‑in‑class partnerships between patient organisations and the life sciences industry, has officially announced its return for 2026.
The Index has grown steadily since its launch in 2020, becoming a recognised platform for showcasing meaningful, innovative and patient‑centred collaboration. Year after year, the PPI highlights projects that move beyond traditional engagement, focusing on those that champion transparency, elevate patient voice, and deliver genuine impact for communities. It has been recognised with industry awards, and is formally endorsed by the sector’s European and UK trade associations – EFPIA and the ABPI.
The 2026 Index promises to be the most ambitious yet, following increased global interest in the programme and a heightened industry focus on demonstrating impact during a period of shifting resources and uncertain geopolitical environments. This year, the PPI is opening its doors even wider, inviting submissions from organisations around the world that are raising the bar for partnership excellence – from LATAM, APAC and the Global South to Europe and the US.
Also new to this year is that there will be a winning entry, followed by GOLD, SILVER and BRONZE and FINALIST standards.
Entries for the 2026 Patient Partnership Index are now open at patientpartnershipindex.com.